BioMarin: Rights To Kuvan Data Licensed To Asubio Pharma (Japan)
This article was originally published in PharmAsia News
Executive Summary
BioMarin Pharmaceutical Inc. has licensed exclusive rights to data and intellectual property contained in the Kuvan new drug application to Japanese drug firm Asubio Pharma Co. Ltd. Asubio will use the data to supplement its current filing to the Japanese Ministry of Health, Labour and Welfare for approval of its BH4 product for the treatment of phenylketornuria in Japan. (Click here for more - May Require Paid Subscription